+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of neoadjuvant carboplatin combined with mirvetuximab soravtansine in adult women with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses folate receptor alpha FR. This phase 2, single-arm study focuses on patients with stage III or IV disease confirmed by specific diagnostic criteria. Mirvetuximab soravtansine is an investigational antibody drug conjugate designed to selectively target and kill cancer cells expressing FR. Participants receive intravenous infusions of mirvetuximab soravtansine together with carboplatin on day 1 of each 21-day cycle, for up to 6 to 9 cycles. Bevacizumab may also be given at the investigators discretion. The treatment is provided in a hospital or clinic setting. The total study duration, including treatment and follow-up, is approximately three years. During the study, participants attend regular visits for medical assessments, blood tests, and imaging scans to monitor their condition and treatment response. Researchers will evaluate the objective response to treatment by independent central review and investigator assessments, as well as safety through adverse event monitoring. Additional measures include progression-free survival, disease control, symptom changes, and surgery outcomes. The study aims to understand how well the treatment works and its safety profile over the course of the trial.

Age: 18Years +FEMALEPhase 2
73 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
S

Actively Recruiting

Researchers are collecting samples and information from patients with pancreatic ductal adenocarcinoma PDAC who will receive standard neoadjuvant chemotherapy treatments, either FOLFIRINOX or Gemcitabine plus Nab-paclitaxel. The study aims to identify blood or tumor tissue biomarkers that might help predict how patients respond to these treatments. This could support selecting the most appropriate therapy for future patients with similar biomarkers. Participants will undergo standard neoadjuvant chemotherapy based on current care guidelines. Two groups are observed patients with borderline resectable PDAC and those with resectable PDAC, classified according to National Comprehensive Cancer Network criteria. Blood samples and archival tumor tissue will be collected to analyze potential biomarkers related to treatment response. During the study, participants pathological responses to treatment will be retrospectively assessed for up to two years. Additional outcomes include survival status and tumor response evaluation using RECIST 1.1 criteria. The study involves monitoring patients clinical data and collecting biological samples without altering their usual care, aiming to gather information that could guide future treatment decisions.

Age: 18Years +All Genders
2 locations
R

Actively Recruiting

Researchers are studying an early intervention led by an oncology clinical nurse specialist that uses a multidisciplinary approach to palliative and survivorship care for adults with metastatic solid tumor malignancies. This randomized control trial aims to compare this nurse-led care model to the standard palliative care approach, focusing on patient-reported symptom burden, overall quality of life, distress, and overall survival. The study targets patients in favorable and very favorable risk groups to evaluate the impact on symptoms like pain, tiredness, nausea, depression, anxiety, and wellbeing. Participants will be assigned randomly to either the nurse-specialist-led intervention or the standard care group. The intervention group receives usual care plus additional coordinated services, patient education, referrals, and ongoing support from the oncology nurse-specialist, including in-person visits and scheduled telephone follow-ups. The standard care group follows usual clinical guidelines with physician and nursing visits scheduled typically at 3, 9, 15, and 24 months. Both groups will complete surveys at multiple timepoints to assess symptoms and quality of life throughout the study period. During the 24-month study, participants will complete validated questionnaires to report symptoms, distress, and quality of life, supported by nursing staff. Data collection occurs at six timepoints using brief surveys that take about 5-6 minutes each. The research team will monitor safety regularly, tracking any adverse events. Survival data will be followed for up to 60 months. Participants can withdraw at any time without affecting their medical care. Total survey time is about 50 minutes for standard care and 85 minutes for the intervention group over 24 months.

Age: 21Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating how doctors use the Percepta4 Nasal Swab test results to manage patients with newly found pulmonary nodules. This observational study aims to see if the test helps reduce invasive procedures in patients with low-risk benign nodules and speeds up treatment for those with high-risk cancerous nodules. The study is prospective, multicenter, and randomized, involving patients whose nodules were found incidentally or through lung cancer screening. Participants will be randomly assigned to two groups one where the Percepta Nasal Swab test result is given to the physician and one where it is not. The study will compare how doctors manage patients nodules with and without access to the test result. About 2400 participants will be enrolled across up to 100 US centers, with enrollment lasting around 24 months. Follow-up will continue for 24 to 30 months or until a lung cancer diagnosis. During the study, researchers will track the number of invasive diagnostic procedures from randomization until the nodule is confirmed benign or stable for up to 30 months. They will also measure the time from randomization to the start of lung cancer treatment. Participants will undergo nasal specimen collection, and clinical history and imaging data will be reviewed. The study observes routine care decisions influenced by the test, without altering standard treatment plans.

Age: 29Years - 85YearsAll Genders
23 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations

1-10 of 17

1